

Inpatient Constipation Among Migraine Patients Prescribed Anti-Calcitonin Gene-related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database

Andrea K Chomistek, ScD - Optum, Boston, MA, US (ORCID: 0000-0002-8764-1446)

Veena Hoffman, MPH - Optum, Boston, MA, US (formerly)

Robert Urman, PhD - Amgen Inc, Thousand Oaks, CA, US

Karminder S Gill, PhD - Amgen Inc, Thousand Oaks, CA, US

Stephen M Ezzy, MS - Optum, Boston, MA, US

Li Zhou, MS - Optum, Boston, MA, US

Andrew S Park, PhD - Amgen Inc, Thousand Oaks, CA, US (formerly)

Brett Loop, MPH - Amgen Inc, Thousand Oaks, CA, US (formerly)

Sandra Lopez-Leon, MD, PhD - Novartis Pharmaceuticals Corp, East Hanover, NJ, US; Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, US

Peter McAllister, MD - New England Institute for Neurology and Headache, Stamford, CT, US

Florence T Wang, ScD - Optum, Boston, MA, US (ORCID: 0000-0001-8776-9434)

Corresponding Author:

Andrea K. Chomistek, ScD

1325 Boylston Street, 11th Floor

Boston, MA 02215

Email: andrea.chomistek@optum.com

SUPPLEMENTARY MATERIAL

Table S1. ICD-10-CM Diagnosis Codes for Serious Complications of Constipation

ICD-10-CM Code	Code description
K56.41	Fecal impaction
K56.49	Other impaction of intestine
K56.60	Unspecified intestinal obstruction
K56.600	Partial intestinal obstruction, unspecified as to cause
K56.601	Complete intestinal obstruction, unspecified as to cause
K56.609	Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction
K59.39	Other megacolon
K62.2	Anal prolapse
K62.3	Rectal prolapse
K60.2	Anal fissure, unspecified
K60.3	Anal fistula
K60.4	Rectal fistula
K60.5	Anorectal fistula
K62.6	Ulcer of anus and rectum
K56.0	Paralytic ileus
K56.7	Ileus, unspecified

Abbreviations: ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification

Table S2. Risk of Inpatient Constipation Within Different Risk Windows Following the Index Date, Erenumab, Other CGRP Monoclonal Antibody Initiators, and Standard of Care Antiepileptic Drug Initiators. Pre- and Post-Propensity Score Matching

	Initiators	Inpatient Constipation	Risk of Inpatient Constipation		Odds Ratio (95% CI) ^a
	N	N	%	95% CI	
	30 Days ^b				
Pre-Matching					
Erenumab	17,394	40	0.23	0.17 - 0.31	---
Other CGRP mAbs	12,844	23	0.18	0.12 - 0.27	---
AEDs	47,953	234	0.49	0.43 - 0.55	---
Post-Matching					
Erenumab-Other CGRP mAbs Comparison					
Erenumab	12,795	27	0.21	0.15 - 0.31	1.16 (0.67 - 2.03)
Other CGRP mAbs	12,651	23	0.18	0.12 - 0.27	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	4,599	13	0.28	0.17 - 0.48	---
Erenumab-AEDs Comparison					
Erenumab	14,973	36	0.24	0.17 - 0.33	0.62 (0.41 - 0.94)
AEDs	14,983	58	0.39	0.30 - 0.50	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,421	4	0.17	0.06 - 0.42	---
	60 Days ^c				
Pre-Matching					
Erenumab	16,729	68	0.41	0.32 - 0.51	---
Other CGRP mAbs	12,110	38	0.31	0.23 - 0.43	---
AEDs	46,046	328	0.71	0.64 - 0.79	---
Post-Matching					
Erenumab-Other CGRP mAbs Comparison					
Erenumab	12,261	47	0.38	0.29 - 0.51	1.20 (0.78 - 1.85)
Other CGRP mAbs	11,927	38	0.32	0.23 - 0.44	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	4,468	21	0.47	0.31 - 0.72	---
Erenumab-AEDs Comparison					
Erenumab	14,360	58	0.40	0.31 - 0.52	0.67 (0.48 - 0.93)
AEDs	14,430	87	0.60	0.49 - 0.74	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,369	10	0.42	0.23 - 0.78	---
	All Available Follow-up During the Study Period ^d				
Pre-Matching					
Erenumab	17,902	284	1.59	1.41 - 1.78	---
Other CGRP mAbs	13,404	144	1.07	0.91 - 1.26	---
AEDs	49,497	985	1.99	1.87 - 2.12	---

Table S2. Risk of Inpatient Constipation Within Different Risk Windows Following the Index Date, Erenumab, Other CGRP Monoclonal Antibody Initiators, and Standard of Care Antiepileptic Drug Initiators. Pre- and Post-Propensity Score Matching

	Initiators	Inpatient Constipation	Risk of Inpatient Constipation		Odds Ratio (95% CI) ^a
	N	N	%	95% CI	
Post-Matching					
Erenumab-Other CGRP mAbs Comparison					
Erenumab	13,200	200	1.52	1.32 - 1.74	1.40 (1.13 - 1.74)
Other CGRP mAbs	13,200	143	1.08	0.92 - 1.27	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	4,702	84	1.79	1.45 - 2.21	---
Erenumab-AEDs Comparison					
Erenumab	15,441	233	1.51	1.33 - 1.71	0.82 (0.69 - 0.97)
AEDs	15,441	284	1.84	1.64 - 2.06	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,461	51	2.07	1.58 - 2.71	---

Abbreviations: AED: antiepileptic drug; CGRP: calcitonin gene-related peptide; CI: confidence interval; mAbs, monoclonal antibodies.

^aOdds ratio comparing propensity score-matched erenumab initiators to propensity-score matched comparators.

^bThe 30-day analysis includes initiators identified from 17 May 2018 - 29 February 2020. Inpatient constipation events were identified within a 30-day risk window following cohort entry, starting from the day after cohort entry through the earliest of: end of the 30-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^cThe 60-day analysis includes initiators identified from 17 May 2018 - 31 January 2020. Inpatient constipation events were identified within a 60-day risk window following cohort entry, starting from the day after cohort entry through the earliest of: end of the 60-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^dThe analysis of all available follow-up during the study period includes initiators identified from 17 May 2018 - 31 March 2020. Inpatient constipation events were identified starting from the day after cohort entry through the earliest of: switching of migraine preventive therapy or end of the study period (31 March 2020).

Table S3. Risk of Serious Complications of Inpatient Constipation Within Different Risk Windows Following the Index Date, Erenumab, Other CGRP Monoclonal Antibody Initiators, and Standard of Care Antiepileptic Drug Initiators. Pre- and Post-Propensity Score Matching

	Initiators	Serious Complications of Inpatient Constipation	Risk of Serious Complications of Inpatient Constipation	
	N	N	%	95% CI
	30 Days^a			
Pre-Matching				
Erenumab	17,394	5	0.03	0.01 - 0.07
Other CGRP mAbs	12,844	1	0.01	0.00 - 0.04
AEDs	47,953	26	0.05	0.04 - 0.08
Post-Matching				
Erenumab-Other CGRP mAbs Comparison				
Erenumab	12,795	1	0.01	0.00 - 0.04
Other CGRP mAbs	12,651	1	0.01	0.00 - 0.04
<i>Unmatched Erenumab Initiators</i>	4,599	4	0.09	0.03 - 0.22
Erenumab-AEDs Comparison				
Erenumab	14,973	4	0.03	0.01 - 0.07
AEDs	14,983	8	0.05	0.03 - 0.11
<i>Unmatched Erenumab Initiators</i>	2,421	1	0.04	0.01 - 0.23
	60 Days^b			
Pre-Matching				
Erenumab	16,729	5	0.03	0.01 - 0.07
Other CGRP mAbs	12,110	2	0.02	0.00 - 0.06
AEDs	46,046	36	0.08	0.06 - 0.11
Post-Matching				
Erenumab-Other CGRP mAbs Comparison				
Erenumab	12,261	1	0.01	0.00 - 0.05
Other CGRP mAbs	11,927	2	0.02	0.00 - 0.06
<i>Unmatched Erenumab Initiators</i>	4,468	4	0.09	0.03 - 0.23
Erenumab-AEDs Comparison				
Erenumab	14,360	4	0.03	0.01 - 0.07
AEDs	14,430	12	0.08	0.05 - 0.15
<i>Unmatched Erenumab Initiators</i>	2,369	1	0.04	0.01 - 0.24
	All Available Follow-up During the Study Period^c			
Pre-Matching				
Erenumab	17,902	19	0.11	0.07 - 0.17
Other CGRP mAbs	13,404	13	0.10	0.06 - 0.17
AEDs	49,497	74	0.15	0.12 - 0.19

Table S3. Risk of Serious Complications of Inpatient Constipation Within Different Risk Windows Following the Index Date, Erenumab, Other CGRP Monoclonal Antibody Initiators, and Standard of Care Antiepileptic Drug Initiators. Pre- and Post-Propensity Score Matching

	Initiators	Serious Complications of Inpatient Constipation	Risk of Serious Complications of Inpatient Constipation	
	N	N	%	95% CI
Post-Matching				
Erenumab-Other CGRP mAbs Comparison				
Erenumab	13,200	12	0.09	0.05 - 0.16
Other CGRP mAbs	13,200	13	0.10	0.06 - 0.17
<i>Unmatched Erenumab Initiators</i>	4,702	7	0.15	0.07 - 0.31
Erenumab-AEDs Comparison				
Erenumab	15,441	16	0.10	0.06 - 0.17
AEDs	15,441	27	0.17	0.12 - 0.25
<i>Unmatched Erenumab Initiators</i>	2,461	3	0.12	0.04 - 0.36

Abbreviations: AED: antiepileptic drug; CGRP: calcitonin gene-related peptide; CI: confidence interval; mAbs, monoclonal antibodies.

^aThe 30-day analysis includes initiators identified from 17 May 2018 - 29 February 2020. Serious complications were identified within 30 days after the inpatient constipation events that were identified in the 30-day risk window following the index date. Serious complications were counted until the earliest of the end of this 30-day period or the end of the study period (31 March 2020). The risk was calculated using the number of initiators as the denominator.

^bThe 60-day analysis includes initiators identified from 17 May 2018 - 31 January 2020. Serious complications were identified within 30 days after the inpatient constipation events that were identified in the 60-day risk window following the index date. Serious complications were counted until the earliest of the end of this 30-day period or the end of the study period (31 March 2020). The risk was calculated using the number of initiators as the denominator.

^cThe analysis of all available follow-up during the study period includes initiators identified from 17 May 2018 - 31 March 2020. Serious complications were identified within 30 days after the inpatient constipation events that were identified following the index date. Serious complications were counted until the earliest of the end of this 30-day period or the end of the study period (31 March 2020). The risk was calculated using the number of initiators as the denominator.

Table S4. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of an Epilepsy Diagnosis During Baseline, Erenumab, Other CGRP Monoclonal Antibody Initiators, and Standard of Care Antiepileptic Drug Initiators. Pre- and Post-Propensity Score Matching

	Initiators ^a	Inpatient Constipation ^b	Risk of Inpatient Constipation		Odds Ratio (95% CI) ^c
	N	N	%	95% CI	
With a Diagnosis of Epilepsy During Baseline					
Pre-Matching					
Erenumab	874	16	1.83	1.13 - 2.95	---
Other CGRP mAbs	521	8	1.54	0.78 - 3.00	---
AEDs	1,905	32	1.68	1.19 - 2.36	---
Post-Matching					
Erenumab-Other CGRP mAbs Comparison					
Erenumab	587	9	1.53	0.81 - 2.89	0.99 (0.38 - 2.58)
Other CGRP mAbs	515	8	1.55	0.79 - 3.04	1.00 (Reference)
Unmatched Erenumab Initiators	287	7	2.44	1.19 - 4.95	---
Erenumab-AEDs Comparison					
Erenumab	746	13	1.74	1.02 - 2.96	0.76 (0.35 - 1.62)
AEDs	611	14	2.29	1.37 - 3.81	1.00 (Reference)
Unmatched Erenumab Initiators	128	3	2.34	0.80 - 6.66	---
Without a Diagnosis of Epilepsy During Baseline					
Pre-Matching					
Erenumab	15,109	68	0.45	0.36 - 0.57	---
Other CGRP mAbs	10,824	42	0.39	0.29 - 0.52	---
AEDs	41,905	366	0.87	0.79 - 0.97	---
Post-Matching					
Erenumab-Other CGRP mAbs Comparison					
Erenumab	11,083	45	0.41	0.30 - 0.54	1.06 (0.69 - 1.61)
Other CGRP mAbs	10,657	41	0.38	0.28 - 0.52	1.00 (Reference)
Unmatched Erenumab Initiators	4,026	23	0.57	0.38 - 0.86	---
Erenumab-AEDs Comparison					
Erenumab	12,923	59	0.46	0.35 - 0.59	0.67 (0.48 - 0.92)
AEDs	13,141	90	0.68	0.56 - 0.84	1.00 (Reference)
Unmatched Erenumab Initiators	2,186	9	0.41	0.22 - 0.78	---

Abbreviations: AED: antiepileptic drug; CGRP: calcitonin gene-related peptide; CI: confidence interval; mAbs, monoclonal antibodies.

^a This table includes initiators identified from 17 May 2018 - 31 December 2019.

^b Inpatient constipation events were identified within a 90-day risk window following the index date, starting from the day after the index date through the earliest of: end of the 90-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^c Odds ratio comparing propensity score-matched erenumab initiators to propensity-score matched comparators.

Table S5. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of Medication Use, Erenumab and Other CGRP Monoclonal Antibody Initiators, Pre- and Post-Propensity Score Matching

	Initiators	Initiators ^a	Inpatient Constipation ^a	Risk of Inpatient Constipation	
		N	N	%	95% CI
Opioids/opiates					
With Use During Baseline	Pre-Matching				
	Erenumab	7,198	72	1.00	0.80 - 1.26
	Other CGRP mAbs	4,780	37	0.77	0.56 - 1.07
	Post-Matching				
	Erenumab	4,989	44	0.88	0.66 - 1.18
	Other CGRP mAbs	4,749	36	0.76	0.55 - 1.05
	<i>Unmatched Erenumab Initiators</i>	2,209	28	1.27	0.88 - 1.83
Without Use During Baseline	Pre-Matching				
	Erenumab	8,785	12	0.14	0.08 - 0.24
	Other CGRP mAbs	6,565	13	0.20	0.12 - 0.34
	Post-Matching				
	Erenumab	6,681	10	0.15	0.08 - 0.28
	Other CGRP mAbs	6,423	13	0.20	0.12 - 0.35
	<i>Unmatched Erenumab Initiators</i>	2,104	2	0.10	0.03 - 0.35
Anticholinergics					
With Use During Baseline	Pre-Matching				
	Erenumab	9,025	69	0.76	0.60 - 0.97
	Other CGRP mAbs	6,133	37	0.60	0.44 - 0.83
	Post-Matching				
	Erenumab	6,313	42	0.67	0.49 - 0.90
	Other CGRP mAbs	6,068	36	0.59	0.43 - 0.82
	<i>Unmatched Erenumab Initiators</i>	2,712	27	1.00	0.69 - 1.44
Without Use During Baseline	Pre-Matching				
	Erenumab	6,958	15	0.22	0.13 - 0.36
	Other CGRP mAbs	5,212	13	0.25	0.15 - 0.43
	Post-Matching				
	Erenumab	5,357	12	0.22	0.13 - 0.39
	Other CGRP mAbs	5,104	13	0.25	0.15 - 0.44
	<i>Unmatched Erenumab Initiators</i>	1,601	3	0.19	0.06 - 0.55
NSAIDs					
With Use During Baseline	Pre-Matching				
	Erenumab	8,782	65	0.74	0.58 - 0.94
	Other CGRP mAbs	6,008	37	0.62	0.45 - 0.85
	Post-Matching				
	Erenumab	6,187	38	0.61	0.45 - 0.84
	Other CGRP mAbs	5,933	37	0.62	0.45 - 0.86
	<i>Unmatched Erenumab Initiators</i>	2,595	27	1.04	0.72 - 1.51
Without Use During Baseline	Pre-Matching				
	Erenumab	7,201	19	0.26	0.17 - 0.41

Table S5. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of Medication Use, Erenumab and Other CGRP Monoclonal Antibody Initiators, Pre- and Post-Propensity Score Matching

	Initiators	Initiators ^a	Inpatient Constipation ^a	Risk of Inpatient Constipation	
		N	N	%	95% CI
	Other CGRP mAbs	5,337	13	0.24	0.14 - 0.42
	Post-Matching				
	Erenumab	5,483	16	0.29	0.18 - 0.47
	Other CGRP mAbs	5,239	12	0.23	0.13 - 0.40
	<i>Unmatched Erenumab Initiators</i>	1,718	3	0.17	0.06 - 0.51
Cation-containing Agents					
With Use During Baseline	Pre-Matching				
	Erenumab	1,020	21	2.06	1.35 - 3.13
	Other CGRP mAbs	640	9	1.41	0.74 - 2.65
	Post-Matching				
	Erenumab	679	15	2.21	1.34 - 3.61
	Other CGRP mAbs	628	9	1.43	0.76 - 2.70
	<i>Unmatched Erenumab Initiators</i>	341	6	1.76	0.81 - 3.79
Without Use During Baseline	Pre-Matching				
	Erenumab	14,963	63	0.42	0.33 - 0.54
	Other CGRP mAbs	10,705	41	0.38	0.28 - 0.52
	Post-Matching				
	Erenumab	10,991	39	0.35	0.26 - 0.48
	Other CGRP mAbs	10,544	40	0.38	0.28 - 0.52
	<i>Unmatched Erenumab Initiators</i>	3,972	24	0.60	0.41 - 0.90
5-HT₃ Receptor Antagonists					
With Use During Baseline	Pre-Matching				
	Erenumab	6,154	63	1.02	0.80 - 1.31
	Other CGRP mAbs	4,117	29	0.70	0.49 - 1.01
	Post-Matching				
	Erenumab	4,257	37	0.87	0.63 - 1.20
	Other CGRP mAbs	4,057	28	0.69	0.48 - 1.00
	<i>Unmatched Erenumab Initiators</i>	1,897	26	1.37	0.94 - 2.00
Without Use During Baseline	Pre-Matching				
	Erenumab	9,829	21	0.21	0.14 - 0.33
	Other CGRP mAbs	7,228	21	0.29	0.19 - 0.44
	Post-Matching				
	Erenumab	7,413	17	0.23	0.14 - 0.37
	Other CGRP mAbs	7,115	21	0.30	0.19 - 0.45
	<i>Unmatched Erenumab Initiators</i>	2,416	4	0.17	0.06 - 0.42

Abbreviations: AED: antiepileptic drug; CGRP: calcitonin gene-related peptide; CI: confidence interval; mAbs, monoclonal antibodies; NSAID: non-steroidal anti-inflammatory drugs; 5-HT₃: serotonin receptor.

^a This table includes initiators identified from 17 May 2018 - 31 December 2019. Inpatient constipation events were identified within a 90-day risk window following the index date, starting from the day after the index date through the earliest of: end of the 90-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

Table S6. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of Medication Use, Erenumab and Standard of Care Antiepileptic Drug Initiators, Pre- and Post-Propensity Score Matching

	Initiators	Initiators ^a	Inpatient Constipation ^a	Risk of Inpatient Constipation	
		N	N	%	95% CI
Opioids/opiates					
With Use During Baseline	Pre-Matching				
	Erenumab	7,198	72	1.00	0.80 - 1.26
	AEDs	20,864	336	1.61	1.45 - 1.79
	Post-Matching				
	Erenumab	6,159	60	0.97	0.76 - 1.25
	AEDs	6,070	86	1.42	1.15 - 1.75
	<i>Unmatched Erenumab Initiators</i>	1,039	12	1.15	0.66 - 2.01
Without Use During Baseline	Pre-Matching				
	Erenumab	8,785	12	0.14	0.08 - 0.24
	AEDs	22,946	62	0.27	0.21 - 0.35
	Post-Matching				
	Erenumab	7,510	12	0.16	0.09 - 0.28
	AEDs	7,682	18	0.23	0.15 - 0.37
	<i>Unmatched Erenumab Initiators</i>	1,275	0	0.00	0.00 - 0.30
Anticholinergics					
With Use During Baseline	Pre-Matching				
	Erenumab	9,025	69	0.76	0.60 - 0.97
	AEDs	22,240	302	1.36	1.21 - 1.52
	Post-Matching				
	Erenumab	7,618	58	0.76	0.59 - 0.98
	AEDs	7,519	84	1.12	0.90 - 1.38
	<i>Unmatched Erenumab Initiators</i>	1,407	11	0.78	0.44 - 1.39
Without Use During Baseline	Pre-Matching				
	Erenumab	6,958	15	0.22	0.13 - 0.36
	AEDs	21,570	96	0.45	0.36 - 0.54
	Post-Matching				
	Erenumab	6,051	14	0.23	0.14 - 0.39
	AEDs	6,233	20	0.32	0.21 - 0.50
	<i>Unmatched Erenumab Initiators</i>	907	1	0.11	0.02 - 0.62
NSAIDs					
With Use During Baseline	Pre-Matching				
	Erenumab	8,782	65	0.74	0.58 - 0.94
	AEDs	24,516	296	1.21	1.08 - 1.35
	Post-Matching				
	Erenumab	7,455	56	0.75	0.58 - 0.97
	AEDs	7,355	72	0.98	0.78 - 1.23
	<i>Unmatched Erenumab Initiators</i>	1,327	9	0.68	0.36 - 1.28

Table S6. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of Medication Use, Erenumab and Standard of Care Antiepileptic Drug Initiators, Pre- and Post-Propensity Score Matching

	Initiators	Initiators ^a	Inpatient Constipation ^a	Risk of Inpatient Constipation	
		N	N	%	95% CI
Without Use During Baseline	Pre-Matching				
	Erenumab	7,201	19	0.26	0.17 - 0.41
	AEDs	19,294	102	0.53	0.44 - 0.64
	Post-Matching				
	Erenumab	6,214	16	0.26	0.16 - 0.42
	AEDs	6,397	32	0.50	0.35 - 0.71
	<i>Unmatched Erenumab Initiators</i>	987	3	0.30	0.10 - 0.89
Cation-containing Agents					
With Use During Baseline	Pre-Matching				
	Erenumab	1,020	21	2.06	1.35 - 3.13
	AEDs	3,027	72	2.38	1.89 - 2.98
	Post-Matching				
	Erenumab	874	17	1.95	1.22 - 3.09
	AEDs	830	19	2.29	1.47 - 3.55
	<i>Unmatched Erenumab Initiators</i>	146	4	2.74	1.07 - 6.83
Without Use During Baseline	Pre-Matching				
	Erenumab	14,963	63	0.42	0.33 - 0.54
	AEDs	40,783	326	0.80	0.72 - 0.89
	Post-Matching				
	Erenumab	12,795	55	0.43	0.33 - 0.56
	AEDs	12,922	85	0.66	0.53 - 0.81
	<i>Unmatched Erenumab Initiators</i>	2,168	8	0.37	0.19 - 0.73
5-HT3 Antagonists					
With Use During Baseline	Pre-Matching				
	Erenumab	6,154	63	1.02	0.80 - 1.31
	AEDs	17,451	295	1.69	1.51 - 1.89
	Post-Matching				
	Erenumab	5,235	54	1.03	0.79 - 1.34
	AEDs	5,093	79	1.55	1.25 - 1.93
	<i>Unmatched Erenumab Initiators</i>	919	9	0.98	0.52 - 1.85
Without Use During Baseline	Pre-Matching				
	Erenumab	9,829	21	0.21	0.14 - 0.33
	AEDs	26,359	103	0.39	0.32 - 0.47
	Post-Matching				
	Erenumab	8,434	18	0.21	0.14 - 0.34
	AEDs	8,659	25	0.29	0.20 - 0.43
	<i>Unmatched Erenumab Initiators</i>	1,395	3	0.22	0.07 - 0.63

Table S6. Risk of Inpatient Constipation Within a 90-day Risk Window Stratified by the Presence of Medication Use, Erenumab and Standard of Care Antiepileptic Drug Initiators, Pre- and Post-Propensity Score Matching

	Initiators	Initiators ^a	Inpatient Constipation ^a	Risk of Inpatient Constipation	
		N	N	%	95% CI
Standard of Care Antiepileptic Drugs^b					
With Use During Baseline	Pre-Matching				
	Erenumab	8,967	62	0.69	0.54 - 0.89
	Post-Matching				
	Erenumab	7,638	52	0.68	0.52 - 0.89
Without Use During Baseline	<i>Unmatched Erenumab Initiators</i>	1,329	10	0.75	0.41 - 1.38
	Pre-Matching				
	Erenumab	7,016	22	0.31	0.21 - 0.47
	Post-Matching				
	Erenumab	6,031	20	0.33	0.21 - 0.51
	<i>Unmatched Erenumab Initiators</i>	985	2	0.20	0.06 - 0.74

Abbreviations: AED: antiepileptic drug; CI: confidence interval; NSAID: non-steroidal anti-inflammatory drugs; 5HT₃: serotonin receptor.

^a This table includes initiators identified from 17 May 2018 - 31 December 2019. Inpatient constipation events were identified within a 90-day risk window following the index date, starting from the day after the index date through the earliest of: end of the 90-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^b The risk of inpatient constipation by prior use of standard of care antiepileptic drugs was only assessed among erenumab initiators.

Table S7. Risk of Inpatient Constipation Within Different Risk Windows, Erenumab and Other CGRP Monoclonal Antibody Initiators, Pre- and Post-Propensity Score Matching: Sensitivity Analysis Among Initiators Whose Index Date was on or after 01 January 2019

	Initiators	Inpatient Constipation	Risk of Inpatient Constipation		Odds Ratio (95% CI) ^a
	N	N	%	95% CI	
	30 Days ^b				
Pre-Matching					
Erenumab	11,067	27	0.24	0.17 - 0.35	---
Other CGRP mAbs	11,403	22	0.19	0.13 - 0.29	---
Post-Matching					
Erenumab	8,375	18	0.21	0.14 - 0.34	1.10 (0.59 - 2.04)
Other CGRP mAbs	11,218	22	0.20	0.13 - 0.30	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,692	9	0.33	0.18 - 0.63	---
	60 Days ^c				
Pre-Matching					
Erenumab	10,402	43	0.41	0.31 - 0.56	---
Other CGRP mAbs	10,669	37	0.35	0.25 - 0.48	---
Post-Matching					
Erenumab	7,841	30	0.38	0.27 - 0.55	1.09 (0.67 - 1.76)
Other CGRP mAbs	10,494	37	0.35	0.26 - 0.49	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,561	13	0.51	0.30 - 0.87	---
	90 Days ^d				
Pre-Matching					
Erenumab	9,656	53	0.55	0.42 - 0.72	---
Other CGRP mAbs	9,904	49	0.49	0.37 - 0.65	---
Post-Matching					
Erenumab	7,250	32	0.44	0.31 - 0.62	0.90 (0.57 - 1.40)
Other CGRP mAbs	9,739	48	0.49	0.37 - 0.65	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,406	21	0.87	0.57 - 1.33	---
	All Available Follow-up During the Study Period ^e				
Pre-Matching					
Erenumab	11,575	148	1.28	1.09 - 1.50	---
Other CGRP mAbs	11,963	120	1.00	0.84 - 1.20	---
Post-Matching					
Erenumab	8,780	101	1.15	0.95 - 1.40	1.14 (0.87 - 1.49)
Other CGRP mAbs	11,767	119	1.01	0.85 - 1.21	1.00 (Reference)
<i>Unmatched Erenumab Initiators</i>	2,795	47	1.68	1.27 - 2.23	---

Abbreviations: AED: antiepileptic drug; CGRP: calcitonin gene-related peptide; CI: confidence interval; mAbs, monoclonal antibodies.

^aOdds ratio comparing propensity score-matched erenumab initiators to propensity-score matched comparators.

^bThe 30-day analysis includes initiators identified from 01 January 2019 - 29 February 2020. Inpatient constipation events were identified within a 30-day risk window following cohort entry, starting from the day after cohort entry through the earliest of: end of the 30-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^cThe 60-day analysis includes initiators identified from 01 January 2019 - 31 January 2020. Inpatient constipation events were identified within a 60-day risk window following cohort entry, starting from the day after cohort entry through the earliest of: end of the 60-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^dThe 90-day analysis includes initiators identified from 01 January 2019 - 31 December 2019. Inpatient constipation events were identified within a 90-day risk window following the index date, starting from the day after the index date through the earliest of: end of the 90-day risk window, switching of migraine preventive therapy, or end of the study period (31 March 2020).

^e The analysis of all available follow-up during the study period includes initiators identified from 01 January 2019 - 31 March 2020. Inpatient constipation events were identified starting from the day after cohort entry through the earliest of: switching of migraine preventive therapy or end of the study period (31 March 2020).

Figure S1a. Distribution of Propensity Scores Prior to Propensity Score Matching, Erenumab and Other CGRP Monoclonal Antibody Initiator Cohorts^a

Abbreviations: CGRP: calcitonin gene-related peptide; mAbs, monoclonal antibodies.

^aInitiators were identified from 17 May 2018 - 31 March 2020. Erenumab initiator cohort n=17,902; other CGRP mAb initiator cohort n=13,404.




Figure S1b. Distribution of Propensity Scores of the Propensity Score-matched Erenumab and Other CGRP Monoclonal Antibody Initiator Cohorts^a

Abbreviations: CGRP: calcitonin gene-related peptide; mAbs, monoclonal antibodies.

^aInitiators were identified from 17 May 2018 - 31 March 2020. PS-matched erenumab initiator cohort n=13,200; PS-matched other CGRP mAb initiator cohort n=13,200.




Figure S2a. Distribution of Propensity Scores Prior to Propensity Score Matching, Erenumab and Standard of Care Antiepileptic Drug Initiator Cohorts^a

Abbreviations: AED: antiepileptic drug.

^aInitiators were identified from 17 May 2018 - 31 March 2020. Erenumab initiator cohort n = 17,902; AED initiator cohort n = 49,497.




Figure S2b. Distribution of Propensity Scores of the Propensity Score-matched Erenumab and Standard of Care Antiepileptic Drug Initiator Cohorts^a

Abbreviations: AED: antiepileptic drug.

^aInitiators were identified from 17 May 2018 - 31 March 2020. PS-matched erenumab initiator cohort n=15,441; PS-matched AED initiator cohort n=15,441.

